SLDB - ソリッド・バイオサイエンシズ (Solid Biosciences Inc.)

SLDBのニュース

   Solid Biosciences: Keep Your Eyes On The Prize, Says Top Analyst  2020/05/11 07:03:25 Smarter Analyst
Solid Biosciences (SLDB) has reported weaker-than-expected 1Q20 results, with FY GAAP EPS of -$2.91 missing Street consensus by $0. The post Solid Biosciences: Keep Your Eyes On The Prize, Says Top Analyst appeared first on Smarter Analyst .
   Solid Biosciences Rips Higher On Positive Biomarker Data For DMD Drug  2019/12/18 14:05:27 Benzinga
Solid Biosciences Inc (NASDAQ: SLDB ) shares are advancing strongly Wednesday following on an update on its clinical development program for its SGT-001, its gene transfer investigational candidate for Duchenne muscular dystrophy, or DMD. Biomarker Data Encouraging Solid Biosciences said biomarker data from two patients dosed in the second cohort of the IGNITE DMD Phase 1/2 study indicated patients showed SGT-001 microdystrophin expression and associated neuronal nitric oxide synthase function. This, according to the company, suggested SGT-001 has the potential to produce therapeutic benefit for DMD patients. DMD, caused by the absence of a protein called dystrophin that aids in keeping muscle cells intact, is a genetic disorder that causes progressive muscle weakness and degeneration, primarily in boys. The company said the previously reported serious adverse event, or SAE, experienced by the third patient in the 2E14 vh/kg dose group has been fully resolved, allowing him to resume normal activities.
   Solid Biosciences (NASDAQ:SLDB) Given New $2.00 Price Target at Credit Suisse Group  2019/11/16 20:10:48 Modern Readers
Solid Biosciences (NASDAQ:SLDB) had its target price cut by Credit Suisse Group from $6.00 to $2.00 in a research report released on Tuesday, The Fly reports. They currently have a hold rating on the stock. Several other research analysts have also recently commented on SLDB. Leerink Swann upgraded shares of Solid Biosciences from a market […]
   Credit Suisse Group Trims Solid Biosciences (NASDAQ:SLDB) Target Price to $2.00  2019/11/16 19:58:34 Modern Readers
Solid Biosciences (NASDAQ:SLDB) had its price target trimmed by Credit Suisse Group from $6.00 to $2.00 in a report published on Tuesday, The Fly reports. The brokerage currently has a hold rating on the stock. SLDB has been the subject of several other reports. ValuEngine upgraded Solid Biosciences from a hold rating to a buy […]
   The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher  2019/11/13 12:10:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov.
   Solid Biosciences: Keep Your Eyes On The Prize, Says Top Analyst  2020/05/11 07:03:25 Smarter Analyst
Solid Biosciences (SLDB) has reported weaker-than-expected 1Q20 results, with FY GAAP EPS of -$2.91 missing Street consensus by $0. The post Solid Biosciences: Keep Your Eyes On The Prize, Says Top Analyst appeared first on Smarter Analyst .
   Solid Biosciences Rips Higher On Positive Biomarker Data For DMD Drug  2019/12/18 14:05:27 Benzinga
Solid Biosciences Inc (NASDAQ: SLDB ) shares are advancing strongly Wednesday following on an update on its clinical development program for its SGT-001, its gene transfer investigational candidate for Duchenne muscular dystrophy, or DMD. Biomarker Data Encouraging Solid Biosciences said biomarker data from two patients dosed in the second cohort of the IGNITE DMD Phase 1/2 study indicated patients showed SGT-001 microdystrophin expression and associated neuronal nitric oxide synthase function. This, according to the company, suggested SGT-001 has the potential to produce therapeutic benefit for DMD patients. DMD, caused by the absence of a protein called dystrophin that aids in keeping muscle cells intact, is a genetic disorder that causes progressive muscle weakness and degeneration, primarily in boys. The company said the previously reported serious adverse event, or SAE, experienced by the third patient in the 2E14 vh/kg dose group has been fully resolved, allowing him to resume normal activities.
   Solid Biosciences (NASDAQ:SLDB) Given New $2.00 Price Target at Credit Suisse Group  2019/11/16 20:10:48 Modern Readers
Solid Biosciences (NASDAQ:SLDB) had its target price cut by Credit Suisse Group from $6.00 to $2.00 in a research report released on Tuesday, The Fly reports. They currently have a hold rating on the stock. Several other research analysts have also recently commented on SLDB. Leerink Swann upgraded shares of Solid Biosciences from a market […]
   Credit Suisse Group Trims Solid Biosciences (NASDAQ:SLDB) Target Price to $2.00  2019/11/16 19:58:34 Modern Readers
Solid Biosciences (NASDAQ:SLDB) had its price target trimmed by Credit Suisse Group from $6.00 to $2.00 in a report published on Tuesday, The Fly reports. The brokerage currently has a hold rating on the stock. SLDB has been the subject of several other reports. ValuEngine upgraded Solid Biosciences from a hold rating to a buy […]
   The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher  2019/11/13 12:10:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov.
   Solid Biosciences: Keep Your Eyes On The Prize, Says Top Analyst  2020/05/11 07:03:25 Smarter Analyst
Solid Biosciences (SLDB) has reported weaker-than-expected 1Q20 results, with FY GAAP EPS of -$2.91 missing Street consensus by $0. The post Solid Biosciences: Keep Your Eyes On The Prize, Says Top Analyst appeared first on Smarter Analyst .
   Solid Biosciences Rips Higher On Positive Biomarker Data For DMD Drug  2019/12/18 14:05:27 Benzinga
Solid Biosciences Inc (NASDAQ: SLDB ) shares are advancing strongly Wednesday following on an update on its clinical development program for its SGT-001, its gene transfer investigational candidate for Duchenne muscular dystrophy, or DMD. Biomarker Data Encouraging Solid Biosciences said biomarker data from two patients dosed in the second cohort of the IGNITE DMD Phase 1/2 study indicated patients showed SGT-001 microdystrophin expression and associated neuronal nitric oxide synthase function. This, according to the company, suggested SGT-001 has the potential to produce therapeutic benefit for DMD patients. DMD, caused by the absence of a protein called dystrophin that aids in keeping muscle cells intact, is a genetic disorder that causes progressive muscle weakness and degeneration, primarily in boys. The company said the previously reported serious adverse event, or SAE, experienced by the third patient in the 2E14 vh/kg dose group has been fully resolved, allowing him to resume normal activities.
   Solid Biosciences (NASDAQ:SLDB) Given New $2.00 Price Target at Credit Suisse Group  2019/11/16 20:10:48 Modern Readers
Solid Biosciences (NASDAQ:SLDB) had its target price cut by Credit Suisse Group from $6.00 to $2.00 in a research report released on Tuesday, The Fly reports. They currently have a hold rating on the stock. Several other research analysts have also recently commented on SLDB. Leerink Swann upgraded shares of Solid Biosciences from a market […]
   Credit Suisse Group Trims Solid Biosciences (NASDAQ:SLDB) Target Price to $2.00  2019/11/16 19:58:34 Modern Readers
Solid Biosciences (NASDAQ:SLDB) had its price target trimmed by Credit Suisse Group from $6.00 to $2.00 in a report published on Tuesday, The Fly reports. The brokerage currently has a hold rating on the stock. SLDB has been the subject of several other reports. ValuEngine upgraded Solid Biosciences from a hold rating to a buy […]
   The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher  2019/11/13 12:10:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov.

calendar